Testing platelet transfusion thresholds in extremely preterm infants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The NeoPlaTT trial aims to determine if a lower platelet transfusion threshold of 20x10^9/L can improve survival without major bleeding in extremely preterm infants born between 23 0/7 to 26 6/7 weeks' gestation. This randomized trial will compare outcomes between infants receiving transfusions at this lower threshold versus a higher threshold. The study focuses on the first week of life, a critical period for these vulnerable infants, to assess the safety and efficacy of the proposed threshold. By addressing the uncertainty surrounding optimal transfusion practices, the trial seeks to enhance clinical outcomes and reduce healthcare costs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Gestational age of 23 0/7 to 26 6/7 weeks
* Postnatal age of \< 48 hours

Exclusion Criteria:

* Comfort care or withdrawal of care planned
* Neonatal alloimmune thrombocytopenia or suspected/confirmed congenital platelet or bleeding disorder
* Receipt of platelet transfusion
* No receipt of Vitamin K
* Parents/guardian decline consent

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting
• Stanford University
  Palo Alto, California, United States Recruiting
• Sharp Mary Birch Hospital for Women & Newborns
  San Diego, California, United States Recruiting
• University of Colorado
  Aurora, Colorado, United States Recruiting
• Emory University
  Atlanta, Georgia, United States Recruiting
• Northwestern Lurie Children's Hospital of Chicago
  Chicago, Illinois, United States Recruiting

Study contacts

• Principal investigator: Ravi M Patel, MD — Emory University
• Study coordinator: Ravi M Patel, MD
• Email: rmpatel@emory.edu
• Phone: 404-727-5905

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting bleeding risk in patients with severe thrombocytopenia using a viscoelastic and clinical score

  We test a new score that combines viscoelastic test results with clinical data to see if we can predict bleeding risk in adults with malignant hematologic disorders and very low platelets.

  Recruiting Centre Hospitalier Annecy Genevois · Épagny, Auvergne-Rhône-Alpes · NCT07653672

• Thromboelastometry to Predict Thrombosis and Survival in Glial Tumor Surgery

  Aimed at people with glial tumors undergoing surgery, the study tests whether thromboelastometry and other blood tests can predict blood-clot risk and survival.

  Recruiting Fundacion Clinic per a la Recerca Biomédica · Barcelona · NCT07813377

• Estimating Platelet Counts with ROTEM PLTEM in Laboring Women with Low Platelets or Heavy Bleeding

  This study tests whether the PLTEM value from ROTEM sigma testing can quickly estimate platelet count in pregnant women with low platelets or severe postpartum hemorrhage to help decisions about anesthesia and transfusions.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid · NCT07616349

• Personalized blood-thinner plan for leg artery disease after repair

  A personalized plan using a blood test to tailor antiplatelet therapy is being tested against standard treatment in adults with PAD after a procedure to restore blood flow.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07613840

• Reference intervals for newborn brain biomarkers

  Measure levels of brain-specific blood proteins (such as GFAP and Tau) in healthy full-term newborns during their first week of life to create normal reference ranges.

  Recruiting University College Cork · Cork · NCT07585149

• Multi-omics search for clotting and bleeding markers in coronary heart disease

  This project will test whether combining proteins, metabolites, genes, sugar tags, and heart images can better predict clotting and major bleeding in people with coronary heart disease on dual antiplatelet therapy.

  Recruiting at 3 sites Chinese Academy of Medical Sciences, Fuwai Hospital · Zhengzhou, Henan and 2 other locations · NCT07523880

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.